Sintx Technologies (SINT) Net Income towards Common Stockholders (2013 - 2026)
Sintx Technologies' (SINT) quarterly Net Income towards Common Stockholders came in at -$2.8 million in Q1 2026, down 22.87% year-on-year from -$3.7 million in Q1 2025, and down 27.36% quarter-over-quarter from -$2.2 million in Q4 2025.
Sintx Technologies (SINT) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Sintx Technologies' Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$2.8 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 22.87% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$17.6 million, a 41.64% decrease from a year earlier, with the FY2025 full-year figure at -$17.1 million, down 54.96% from the prior year.
- Net Income towards Common Stockholders eased to -$2.8 million in Q1 2026 per SINT's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$1.7 million in Q4 2024 and bottomed at -$10.3 million in Q3 2025.
- The 5-year median for Net Income towards Common Stockholders is -$2.7 million (2022), against an average of -$3.7 million.
- Across the five-year window, Net Income towards Common Stockholders plunged 294.0% in 2022 and soared 72.4% in 2023, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$8.4 million in 2022, then surged by 72.4% to -$2.3 million in 2023, then increased by 26.97% to -$1.7 million in 2024, then slumped by 30.68% to -$2.2 million in 2025, then decreased by 27.36% to -$2.8 million in 2026.
- Per Business Quant, the three latest SINT Net Income towards Common Stockholders figures stand at -$2.8 million (Q1 2026), -$2.2 million (Q4 2025), and -$10.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.59 Bn | 176.29 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 129.07 Bn | 126.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.58 Bn | 99.36 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.64 Bn | 67.19 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.38 Bn | 44.71 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.13 Bn | 25.84 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.27 Bn | 21.15 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Sintx Technologies | 5.70 Mn | 3.81 Mn | 144,000.00 | -2.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.82 Mn |
| Dec 31, 2025 | -2.22 Mn |
| Sep 30, 2025 | -10.26 Mn |
| Jun 30, 2025 | -2.32 Mn |
| Mar 31, 2025 | -2.30 Mn |
| Dec 31, 2024 | -1.70 Mn |
| Sep 30, 2024 | -6.24 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | -3.73 Mn |
| Dec 31, 2023 | -2.32 Mn |
| Sep 30, 2023 | -3.19 Mn |
| Jun 30, 2023 | -2.48 Mn |
| Mar 31, 2023 | -4.44 Mn |
| Dec 31, 2022 | -8.41 Mn |
| Sep 30, 2022 | -2.72 Mn |
| Jun 30, 2022 | -2.51 Mn |
| Mar 31, 2022 | -2.85 Mn |
| Dec 31, 2021 | -2.13 Mn |
| Sep 30, 2021 | -2.34 Mn |
| Jun 30, 2021 | -2.20 Mn |